GlassScriptPhysician profile
Marcus L Scarbrough
NPI 1225069404
$1,067.00
in general payments reported to CMS, 2019-2025
19 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.54 · 2023: $235 · 2024: $320 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $249.67 | 2023-2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $142.65 | 2023-2025 | Otezla, Repatha, Repatha |
| Nevro Corp. | $89.27 | 2024 | Senza |
| Novartis Pharmaceuticals Corporation | $87.83 | 2023-2024 | |
| Lilly USA, LLC | $63.99 | 2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $58.32 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Eisai INC. | $47.83 | 2024-2025 | |
| Pfizer INC. | $47.80 | 2024-2025 | |
| Shield Therapeutics INC | $40.26 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.24 | 2023-2024 | Xifaxan |
| Lundbeck LLC | $32.09 | 2024 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $25.54 | 2022 | |
| Spr Therapeutics, INC | $25.23 | 2025 | Sprint Pns System |
| Otsuka America Pharmaceutical, INC. | $24.73 | 2025 | Rexulti |
| Optinose US, INC. | $23.22 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.74 | 2025 | Dexcom G6 Transmitter |
| Neurelis, INC. | $20.02 | 2024 | Valtoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.69 | 2025 | Jardiance |
| Ardelyx, INC. | $15.88 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Scarbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.